ID Week

Remdesivir was the first FDA-approved drug to fight COVID-19, but how has it held up against the latest variants?

Northwestern Medicine developed a testing strategy using a two-step algorithm to improve diagnostic accuracy and treatment outcomes.

One HIV clinical care program in Delaware looked into strategies to increase immunization rates to decrease severe disease as well as minimize hospital capacity.

It’s not enough to have accurate infectious disease diagnostics, they must be accessible to the patients most affected.

Encouraging ICU physicians to utilize rapid diagnostics, like the FilmArray Pneumonia Panel, may improve patient outcomes.

Venatorx Pharmaceuticals is advancing the fight against difficult-to-treat, drug-resistant, gram-negative bacteria with a successful phase 3 clinical trial of its investigational antibiotic cefepime-taniborbactam.

Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in an hour.

A multicenter, retrospective observational study looked at appropriate antibiotics for the treatment in this patient population.

Investigators examined the profiles of the HepB-CPG vaccine and HepB-alum vaccines to study the onset of select immune-mediated diseases, herpes zoster, or anaphylaxis.

A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.

Using the DRIP Score along with newer diagnostic technology may determine the course of antibiotics for certain patients with pneumonia more efficiently and efficaciously.

A member of the Infectious Diseases Society of America (IDSA) leadership feels there is some inroads being made in Congress for this antimicrobial resistance legislation.

What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.

After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.

Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.

During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.

Dr. Simon Portsmouth elaborates on the potential of Shionogi's cefiderocol, an up-and-coming agent in the fight against antimicrobial resistance.

The phase 3 study met its primary and secondary end points of all-cause mortality, microbiological eradication rates, and new Staphylococcus aureus bacteremia complications.

Evidence on this has been conflicting and a poster presented at ID Week offers more insights on this significant topic.

At IDWeek 2022, Erica Stohs, MD, MPH, presented surprising findings about unnecessary antibiotics in a cohort coinfected with COVID-19 and pneumonia.

The investigational vaccine was effective in reducing both lower respiratory tract and all respiratory tract infections.

After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.

There is a significant need for C difficile treatments that don’t destroy the microbiome.

Despite no significant reduction in time to discharge or recovery, inhalable SNG001 may lessen common symptoms of “long COVID.”

Breakthrough COVID-19 infections were rare in fully vaccinated individuals, but the average breakthrough occurred just under 50 days after complete vaccination.

A retrospective study of a Colombian cohort examined the causes of antiretroviral switch in people living with HIV/AIDS, as well as the time to ART switch.

At IDWeek 2022, antimicrobial stewardship was front and center. However, not all tests are created equal.

There is an evolution of thinking about how this is treated and investigational therapies are looking to help these patients improve not only their medical conditions but give them back their quality-of-life.

Evidence demonstrates how these therapies are prescribed around patients’ races.

COVID-19 isolation wards should employ additional contact precautions and environmental cleaning alongside regular COVID-19 precautions, such as personal protective equipment, in order to prevent multidrug-resistant infections.